MULTIPLYING WEIGHT-LOSS MEDS WHEN MIKE DOUSTDAR STARTED AS A SUMMER EMPLOYEE making copies at Novo Nordisk—a teenager living in Austria after fleeing unrest in his home country of Iran at 12—he never

For decades, the global branded food and drinks sector was the favoured choice of the defensive investor. It offered a simple, reliable formula for wealth creation that relied on famous names, predict

It is nearly eight years since Sam Isaly abruptly stepped down from OrbiMed, the managers of the Worldwide Healthcare Trust (LSE: WWH). In the 22 years in which he was lead manager, WWH achieved an an

Relax about Relx: “All eyes are on software and legal firms like Relx,” says Chris Beauchamp of investing platform IG. AI start-up Anthropic has parked “its tanks on their lawn in a clear threat to th

Around 2.5 million people are currently taking weight-loss drugs in the UK. That’s almost 3.5% of the population injecting drugs such as Mounjaro and WeGovy and facing up to access barriers, price fluctuations and supply shortages. But, as four men explain, the hype around these drugs is very real

Companies in the news and how they were assessed